Legal Representation
Attorney
Todd A. Sullivan
USPTO Deadlines
Next Deadline
1204 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-11-01)
Due Date
November 01, 2028
Grace Period Ends
May 01, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 4, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Feb 4, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 4, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Feb 4, 2025 | EWOR | I | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | Loading... |
| Feb 4, 2025 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
| Feb 4, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 4, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Nov 1, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 1, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Aug 16, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 16, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 27, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 8, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 6, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 5, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 5, 2022 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Jan 13, 2022 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Jan 13, 2022 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Jan 13, 2022 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Nov 29, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 29, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 15, 2021 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Oct 5, 2021 | GNS2 | O | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | Loading... |
| Oct 5, 2021 | GNSI | S | INQUIRY TO SUSPENSION E-MAILED | Loading... |
| Oct 5, 2021 | CNSI | R | SUSPENSION INQUIRY WRITTEN | Loading... |
| Aug 25, 2021 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | Loading... |
| Jan 5, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jan 5, 2021 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jan 5, 2021 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jan 5, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jan 5, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Dec 7, 2020 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Dec 7, 2020 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Dec 7, 2020 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Dec 4, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 4, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 25, 2020 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Nov 23, 2020 | GNS2 | O | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | Loading... |
| Nov 23, 2020 | GNSI | S | INQUIRY TO SUSPENSION E-MAILED | Loading... |
| Nov 23, 2020 | CNSI | R | SUSPENSION INQUIRY WRITTEN | Loading... |
| Nov 2, 2020 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | Loading... |
| Nov 2, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Feb 26, 2020 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Feb 26, 2020 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Feb 26, 2020 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Feb 11, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 10, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 10, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 9, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations, namely, anti-cancer and immunosuppression preparations; pharmaceuticals, namely, anti-cancer and immunosuppression preparations; chemico-pharmaceutical preparations, namely, chemical preparations for medical purposes for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances, namely, pharmaceutical products for the treatment of cancer and immunosuppression; pharmaceutical preparations, namely, anti-cancer preparations for veterinary use; chemical preparations for pharmaceutical purposes, namely, chemical preparations for the treatment of cancer and immunosupression; pharmaceutical preparations for human use, namely, pharmaceutical preparations for human use in the treatment of cancer and immnunosupression; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for use in oncology; diagnostic preparations for medical purposes; diagnostic agents for pharmaceutical use; diagnostic agents for medical use; diagnostic preparations for veterinary purposes; clinical diagnostic reagents for medical use; diagnostic chemical reagents for medical use; anti-cancer drugs, namely, anti-cancer preparations; pharmaceutical compounds for treating cancer and immunosuppression; anti-cancer preparations; anti-cancer preparations of chemical origin; biopharmaceuticals, namely, anti-cancer preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics; antibodies being pharmaceutical preparations for the treatment of cancer and immunosuppression; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression with agents including amatoxin
Class 042
Pharmaceutical research services; medical and pharmacological research services; pharmaceutical products development; development of pharmaceutical preparations and medicines; consultancy relating to pharmaceutical research and development; provision of medical research services; scientific research; medical research; biomedical research services; research relating to biotechnology; research on the subject of pharmaceuticals; consultancy relating to research in the field of pharmacogenetics; research and development in the pharmaceutical and biotechnology fields; research and development in the field of diagnostic preparations; research and development in the field of biotechnology; pharmaceutical research and development for the pharmaceutical industry; research and development services in the field of antibody technology; research and development services in the field of antibodies; scientific laboratory services relating to the production of monoclonal antibodies; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression
Class 044
Pharmaceutical advice; pharmaceutical consultation services; consultancy and information services relating to pharmaceutical products; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression
Classification
International Classes
005
042
044